Effects of Recombinant Human Erythropoietin on Platelet Function in Healthy Subjects
Drug: Recombinant human erythropoietin alfa (drug)
Drug: Aspirin (drug)
Drug: Clopidogrel (drug)
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||Effects of Recombinant Human Erythropoietin on Platelet Function in Healthy Subjects|
- Bleeding time
- Platelet function assay closure time
- Complete Blood Count
- von Willebrand factor
|Study Start Date:||October 2005|
|Estimated Study Completion Date:||July 2006|
Anti-apoptotic effects of erythropoietin in experimental myocardial infarction and ischemia-reperfusion injury suggest potential for therapeutic benefit in patients with acute MI. Before the therapeutic potential of rHuEpo in acute MI can be tested in large clinical trials, more information on the effects of short-term rHuEpo on platelet function are needed. Accordingly, the current proposal aims to determine the effects of 3 doses of rHuEpo (100U/kg, 200U/kg and 400U/kg daily for 3 days) on platelet function and other safety measures in healthy subjects.
Specific Aim: To determine the effects of three ascending doses of rHuEpo vs. placebo on in vivo and in vitro platelet function in healthy subjects treated with aspirin and clopidogrel.
Hypotheses to be tested: 1) 1) Short-term administration of rHuEpo does not alter bleeding time responses to aspirin and clopidogrel when compared with placebo. 2) Short-term administration does not alter in vitro platelet aggregation responses to aspirin and clopidogrel when compared with placebo.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00368238
|United States, Connecticut|
|Yale University School of Medicine|
|New Haven, Connecticut, United States, 06510|
|Principal Investigator:||Stuart D Katz, MD||Yale University|